Yield of contact investigations in households of patients with drug-resistant tuberculosis: Systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 58, Issue 3, 2014, Pages 381-391

  Shah, N Sarita ^a,d   Yuen, Courtney M ^b   Heo, Moonseong ^a   Tolman, Arielle W ^b   Becerra, Mercedes C ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS IN HEALTH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

contact; drug resistance; transmission; tuberculosis

Indexed keywords

BACTERIAL TRANSMISSION; DISEASE COURSE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; EARLY DIAGNOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENOTYPE; HIGH RISK PATIENT; HOUSEHOLD; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS CONTROL;

CONTACT; DRUG RESISTANCE; TRANSMISSION; TUBERCULOSIS;

CONTACT TRACING; FAMILY CHARACTERISTICS; HUMANS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84892711556     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit643     Document Type: Review

References (59)

1. World Health Organization. Global tuberculosis report 2012. Geneva, Switzerland: WHO, 2013.
2. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:113-19.
3. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830-43.
4. Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR TB treatment in a high HIV-prevalence setting in southern Africa. PLoS One 2009; 4:e7186.
5. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-61.
6. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR TB): 2010 global report on surveillance and response. Geneva, Switzerland: WHO, 2010.
7. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
8. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181:80-6.
9. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372:1403-9.
10. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30:623-6.
11. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359:563-74.
12. Satti H, Seung K, Keshavjee S, et al. Extensively drug-resistant tuberculosis, Lesotho. Emerg Infect Dis 2008; 14:992-3.
13. Shah NS, Pratt R, Armstrong L, et al. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300:2153-60.
14. Andrews RH, Evadatta S, Ox W, et al. Prevalence of tuberculosis among close family contacts of tuberculous patients in south India, and influence of segregation of the patient on early attack rate. Bull World Health Organ 1960; 23:463-510.
15. Sepkowitz KA. How contagious is tuberculosis? Clin Infect Dis 1996; 23:954-62.
16. World Health Organization. Recommendations for investigating contacts of persons with infectious tuberculosis in low-and middle-income countries. Geneva, Switzerland: WHO, 2013.
17. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:359-68.
18. Fox GJ, Barry SE, Britton WJ, et al. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 2013; 41:140-56.
19. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52:119-26.
20. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22:209-12.
21. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17:857-72.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
23. Centers for Disease Control and Prevention. Two simultaneous outbreaks of multidrug-resistant tuberculosis-Federated States of Micronesia, 2007-2009. MMWR Morb Mortal Wkly Rep 2009; 58:253-6.
24. Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 1999; 29:85-92.
25. Bayona J, Chavez-Pachas AM, Palacios E, et al. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2003; 7(12 suppl 3):S501-9.
26. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377: 147-52.
27. Grandjean L, Crossa A, Gilman RH, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 2011; 15:1164-9, i.
28. Huang YW, Shen GH, Lee JJ, et al. Latent tuberculosis infection among close contacts of multidrug-resistant tuberculosis patients in central Taiwan. Int J Tuberc Lung Dis 2010; 14:1430-5.
29. Johnson KR, Braden CR, Cairns KL, et al. Transmission of Mycobacterium tuberculosis from medical waste. JAMA 2000; 284:1683-8.
30. Kritski AL, Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153:331-5.
31. Mehta J, Keith R, Al HM, et al. Mini epidemic of isoniazide resistant TB in rural TN: a need for supervised preventive therapy. Tenn Med 2009; 102:41-4.
32. Miramontes R, Lambert L, Haddad MB, et al. Public health response to a multidrug-resistant tuberculosis outbreak among Guatemalans in Tennessee, 2007. South Med J 2010; 103:882-6.
33. Mokaddas E, Ahmad S, Abal AT, et al. Molecular fingerprinting reveals familial transmission of rifampin-resistant tuberculosis in Kuwait. Ann Saudi Med 2005; 25:150-3.
34. Neely F, Maguire H, Le BF, et al. High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis. J Public Health (Oxf) 2010; 32:44-51.
35. Perri BR, Proops D, Moonan PK, et al. Mycobacterium tuberculosis cluster with developing drug resistance, New York, New York, USA, 2003-2009. Emerg Infect Dis 2011; 17:372-8.
36. Pineiro Perez R, Mellado Pena MJ, Mendez Echevarria A, et al. Exposi-cion a tuberculosis multirresistente: estudio y seguimiento de nueve ninos [in Spanish]. An Pediatr (Barc) 2008; 68:490-5.
37. Tuberculosis Research Centre, Indian Council of Medical Research (ICMR), Chennai, India. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases. Int J Tuberc Lung Dis 2011; 15:782-8.
38. Reichler MR, Valway SE, Onorato IM. Transmission in the United States Virgin Islands and Florida of a multidrug-resistant Mycobacterium tuberculosis strain acquired in Puerto Rico. Clin Infect Dis 2000; 30:617-8.
39. Salazar-Vergara RM, Sia IG, Tupasi TE, et al. Tuberculosis infection and disease in children living in households of Filipino patients with tuberculosis: a preliminary report. Int J Tuberc Lung Dis 2003; 7(12 suppl 3):S494-500.
40. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109:765-71.
41. Singla N, Singla R, Jain G, et al. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis 2011; 15:1326-30.
42. Snider DE Jr, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132:125-32.
43. Steiner M, Chaves AD, Lyons HA, et al. Primary drug-resistant tuberculosis. Report of an outbreak. N Engl J Med 1970; 283:1353-8.
44. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5:321-8.
45. van Zyl S, Marais BJ, Hesseling AC, et al. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006; 10:13-8.
46. Vella V, Racalbuto V, Guerra R, et al. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 2011; 15:1170-5.
47. Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26:462-4.
48. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3:13-21.
49. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2009; 15(suppl 1):66-8.
50. Gagneux S, Long CD, Small PM, et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312:1944-6.
51. Gagneux S, Burgos MV, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2:e61.
52. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10:1117-21.
53. Verver S, Warren RM, Munch Z, et al. Transmission of tuberculosis in a high incidence urban community in South Africa. Int J Epidemiol 2004; 33:351-7.
54. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva, Switzerland: WHO, 2008.
55. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA 2009; 106:7672-7.
56. Dowdy DW, Chaisson RE, Maartens G, et al. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 2008; 105:11293-8.
57. Becerra MC, Franke MF, Appleton SC, et al. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J 2013; 32:115-9.
58. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
59. Lawn SD, Bekker LG, Middelkoop K, et al. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42:1040-7.